Belite Bio, Inc. (NASDAQ: BLTE) reported its preliminary, unaudited financial results for the fourth quarter and full year ended December 31 2025. The company posted a net loss of $77.6 million for the year, a sharp increase from the $36.1 million loss in 2024, driven by higher research and development and selling, general and administrative expenses. Cash and cash equivalents rose to $352.9 million, up from $31.7 million at the end of 2024, reflecting the $402 million raised in a 2025 underwritten public offering of American Depositary Shares.
The company highlighted that its Phase 3 DRAGON trial for Stargardt disease delivered topline results on December 1 2025 and is progressing toward a December 2025 topline. Management plans to submit a new drug application to the FDA in the second quarter of 2026. The cash position provides a runway for U.S. commercialization, estimated at $200 million, without immediate dilution risk. Operating expenses for the year were $45.4 million for research and development and $38.8 million for selling, general and administrative costs, largely driven by share‑based compensation and professional service fees.
Belite Bio’s earnings announcement marked a key milestone for the clinical‑stage biopharma, providing investors with updated financial metrics and a clearer view of the company’s path to regulatory approval and eventual commercialization. The disclosure of cash reserves, expense trends, and upcoming regulatory milestones underscores the company’s strategic focus on advancing its oral therapy for retinal diseases.
Management emphasized the significance of the DRAGON trial results, stating, “2025 marked a defining year for Belite, highlighted by positive topline results from our pivotal Phase 3 DRAGON trial, establishing tinlarebant as a potential first‑in‑class therapy for Stargardt disease. Combined with the completion of our $402 million public offering, we believe the Company is well positioned for the next phase of execution, and we remain on track to submit an NDA to the FDA in the second quarter of 2026 as we advance toward our goal of bringing the first approved treatment for Stargardt disease to people living with this debilitating disease.”
The company’s net loss widened in absolute terms but the loss per share beat analyst expectations by $0.18, driven largely by substantial interest income from the enlarged cash and investment holdings. While the company remains pre‑revenue, the strong cash position and successful Phase 3 trial results provide a solid foundation for future regulatory submissions and potential commercialization. Investors and analysts noted that the earnings beat was offset by the company’s continued heavy investment in clinical development, which is typical for a late‑stage biopharma. The market reaction was muted, with a slight negative pre‑market move, suggesting that investors are focusing on the long‑term clinical and regulatory pathway rather than short‑term earnings performance.
The company’s guidance remains unchanged, with management reaffirming its commitment to submit an NDA in Q2 2026 and maintain a robust cash runway for U.S. commercialization. The results reinforce Belite Bio’s position as a first‑in‑class therapy provider for Stargardt disease and highlight the company’s ability to secure significant capital to support its clinical development program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.